<DOC>
	<DOC>NCT02941835</DOC>
	<brief_summary>The PROBI is a phase I/II trial assessing the feasibility of preoperative whole breast irradiation in female patients with low to intermediate risk breast cancer, who undergo breast conserving therapy, including a boost dose of irradiation. An additional goal of this study is to assess tumor response to radiotherapy, by imaging modalities (PET-CT and MRI) and pathology</brief_summary>
	<brief_title>Preoperative Breast Irradiation</brief_title>
	<detailed_description />
	<criteria>Histologically proven invasive breast carcinoma cT12N0 breast cancer cM0 Indication for an additional boost to the tumor bed, i.e.: female patients â‰¤ 50 years AND/OR histological grade III carcinoma AND/OR lymph angio invasion planned breast conserving surgery (without neoadjuvant systemic therapy) Ability to undergo irradiation and surgery Signed written informed consent prior surgery or radiotherapy for the protocol tumor neoadjuvant chemotherapy or hormonal therapy planned oncoplastic reduction mammoplasty cTis no indication for an additional boost to the tumor bed extensive calcifications on mammagram (Birads 3,4 or 5) cT34 and/or cN13 invasive carcinoma distant metastasis</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>pre-operative radiotherapy</keyword>
</DOC>